| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 167,502 | 125,735 |
| Proceeds from issuance of common stock, net of issuance costs-At The Market Offering | 24,901 | - |
| Proceeds from espp purchase | 820 | 820 |
| Proceeds from exercise of common stock options | 1,928 | 1,544 |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | - | 24,984 |
| Net cash provided by financing activities | 27,649 | 27,348 |
| Net increase in cash, cash equivalents and restricted cash | 214,549 | 30,267 |
| Cash and cash equivalents at beginning of period | 85,183 | - |
| Cash and cash equivalents at end of period | 299,732 | - |
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)